Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) Comparison with companies in other sectors?

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has a share price of 372.41M. You can analyze Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) competitors across different market sectors through stock heatmaps.

What are 2315.HK's NET and operating margins?

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) operating margin is around -0.09, and net profit margin is approximately -0.24 as of the latest reports.

In what way does 2315.HK's earnings per share (EPS) trend reflect its financial momentum?

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) EPS is 0.09 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is 282.78, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. like P/E which is -63.21, P/B which is 11.16, and PEG which is -3.16. Compare them with sector averages to evaluate if the stock is priced fairly.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

2315.HK•HKSE

Healthcare

Biotechnology

HK$25.26

HK$-0.39(-1.52%)

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.09

P/E Ratio

282.78

ROE

-0.19%

Net Margin

-0.24%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$9.48B

Shares OutstandingTotal number of shares issued

$372.41M

Book Value/ShareNet worth per share

$2.11

Revenue/ShareAnnual revenue per share

$1.52

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.09

Net MarginNet income as percentage of revenue

-24.32%

Operating MarginOperating income as percentage of revenue

-8.51%

ROEReturn on shareholders' equity

-19.00%

ROAReturn on total assets

-6.10%

ROCEReturn on capital employed

-2.74%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.10

Cash/ShareCash and equivalents per share

$0.96

FCF YieldFree cash flow as percentage of market cap

-0.47%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2315.HKFinancial Ratios Analysis details for 2315.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2315.HKSector Benchmarking details for 2315.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

For Biocytogen Pharmaceuticals (Beijing) Co., Ltd., essential financial indicators include EPS 0.09, PE 282.78, and ROE -0.19. These key ratios reveal insights into Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Biocytogen Pharmaceuticals (Beijing) Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Metrics like Net Margin -24.32% and ROA -6.10% shed light on how well Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Biocytogen Pharmaceuticals (Beijing) Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Using ratios such as P/B Ratio 11.16 and PEG Ratio -3.16, investors can assess whether Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.68 and Cash Flow $-0.10, provide a snapshot of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Biocytogen Pharmaceuticals (Beijing) Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Investing in Biocytogen Pharmaceuticals (Beijing) Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Biocytogen Pharmaceuticals (Beijing) Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;